Join the club for FREE to access the whole archive and other member benefits.

Cancer breathalyser starts clinical trial for wide range of cancers

VOCs in breath captured by mask sent to lab for diagnosis - avoids invasive tests


Key points from article :

Breath Biopsy device is designed to detect cancer hallmarks in molecules exhaled by patients.

1,500 participants being recruited for two-year trial at Addenbrooke’s hospital in Cambridge.

Will be tested with oesophageal, stomach, prostate, kidney, bladder, liver and pancreatic cancers.

Could detect cancer earlier, giving patients the best chance of surviving their disease.

Clinical trial is being run by CRUK in conjunction with Owlstone Medical, which invented the test.

Participants will breathe into the cancer breathalyser for 10 minutes.

Volatile organic compounds (VOCs) collected by the test will be sent to a laboratory for analysis.

Could reduce harm by sparing patients from more invasive tests that they don’t need.

Mentioned in this article:

Click on resource name for more details.

Billy Boyle

Co-Founder and CEO at Owlstone Medical Ltd.

Cancer Research UK

Independent cancer charity focused on saving lives through research, influence and information

Owlstone Medical

Company focused to development of non-invasive diagnostics for cancer and inflammatory diseases.

Rebecca Fitzgerald

Interim Director of the MRC Cancer Unit, Hutchison-MRC Research Centre.

Topics mentioned on this page:
Diagnostics, Cancer